🇧🇷Brazil
Protocol Approval Delays Driving Trial Start-Up Time Drag
1 verified sources
Definition
Prolonged IRB/IACUC approval and site activation processes delay trial initiation by weeks to months, incurring daily operational costs without revenue generation. Average site activation takes 13-25 weeks, with interventions showing potential 45% reduction.[2]
Key Findings
- Financial Impact: $55,716 per day Phase III trial delay; ~$390,000 per delayed week per site
- Frequency: Recurring per trial start-up cycle
- Root Cause: Complex administrative coordination involving contracts, feasibility, and ethics reviews
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
CRO Start-Up Managers, Site Principal Investigators, Sponsor Finance Teams
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Evidence Sources:
Related Business Risks
High IRB/Ethics Committee Fees and Site Activation Delays
$1,000-$5,000+ per site IRB fee; $30,000-$200,000 total per site activation
Excessive Protocol Amendments in Research Protocol Development
$250,000-$450,000 per amendment
Idle Resources from Protocol Amendment Cycle Times
$453,932 average per amendment implementation
High Development Costs and Funding Shortfalls
$Hundreds of millions per project in unrecouped development costs
Civil Money Penalties for ClinicalTrials.gov Non-Compliance in Biotech Trials
$10,000 per day per violation
Publish-or-Perish Conflicts with Patent Timing
$Reduced royalties over shortened patent life (estimable in millions for successful drugs)